Statistics from Altmetric.com
Imatinib, a tyrosine kinase inhibitor, has transformed treatment options for patients with chronic myeloid leukaemia (CML). It is effective in the management of all phases of CML by selectively inhibiting the BCR-ABL protein, the molecular consequence of the Philadelphia chromosome (Ph). The overall survival and disease-free survival of CML have significantly improved with the use of imatinib. We report a novel and dose-limiting complication of imatinib therapy.
We report a 58-year-old man with Ph-positive CML who was initially treated with hydroxyurea followed by alpha-interferon and imatinib. He achieved complete cytogenetic and molecular remission on combination therapy at 6 and 30 months, respectively. Due to extreme fatigue, interferon therapy (25 μg once weekly) was discontinued after 3 years with good response. Subsequent to 5.5 years of imatinib therapy, he complained of bilateral lower limb paraesthesia. His symptoms progressed over the next 6 months resulting in ankle weakness and tripping. On examination, he had a brisk ankle jerk with diminished vibration and position sense. His C-reactive protein, blood …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.